Skip to main content
Clinical Trials/NCT00477685
NCT00477685
Completed
Not Applicable

Study of the Safety and Effectiveness of the OculusGenTM Collagen Matrix Implant as an Aid in Phacotrabeculectomy Surgery

Pro Top & Mediking Company Limited1 site in 1 country10 target enrollmentMay 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Glaucoma
Sponsor
Pro Top & Mediking Company Limited
Enrollment
10
Locations
1
Primary Endpoint
Preoperative and Postoperative Intraocular Pressure
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

  1. . Study Objective: The objective of this study is to determine the safety and effectiveness of the OculusGenTM Biodegradable Collagen Matrix Implant in phacotrabeculectomy surgery. The primary endpoint is to prove the effectiveness via the reduction of Intraocular Pressure, and the secondary endpoint is to prove the safety via the incidence of complications and adverse events.
  2. . Study Design: The study is designed as a historical controlled study. Patient who meet the inclusion/exclusion criteria and sign the informed consent form will be included for this study. The allocation of subjects is non-randomized, and there is a single group for assignment.
  3. . Follow-Up: This investigation is including 7 post-operative visits and follow-up within 6 months from the date of surgery. Patients should be seen at postoperative days 1, 7, 14, 30, 60, 90 and 180. The visit window of ± 7 days is allowed for the 30, 60, 90 and 180 day visits. The further follow-up of subject after trial is continually tracked by the investigator.

Detailed Description

ologen collagen matrix is applied for the phacotrabec surgery.

Registry
clinicaltrials.gov
Start Date
May 2007
End Date
October 2011
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Preoperative and Postoperative Intraocular Pressure

Time Frame: baseline and 90 days

The preoperative and postoperative intraocular pressure is measured as mmHg at baseline and 90 days.

Secondary Outcomes

  • Number of Participants With Any Complications or Adverse Events.(180 day)

Study Sites (1)

Loading locations...

Similar Trials